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Item M P Difl p-value
Visitsand drugs 1861 1646 15 NS
Starl up costs (inclM) 972 0 972 NA
Hospitalcsre (exd Htx) 2687 4448 -1762 >0.05
Hesrttrsneplantation (Hti) 141t 13740 -12329 <0.001
Totslcosts (inclHfx) 6931 20034 -13104 <0.001
Conclusion: The uae of metoprolol in a population of congestive heart
failure due to idiopathic dilated cardiomyopathy (mainly NYHAclasa II and Ill
patients) is highly coat effective and should therefore always be considered
as complementary to reduce morbidity and health care coata.
m1017145 Impact of Carvedilol Therapy for Heart Failure onCosts of Cardiovascular-Related Hospitalization
G.Oster, J. Menzin, R.E. Richner, S. Young, M. Vera, MB. Fowler. Po/icy
Arra/ysis Inc., Brocddine,MA; SrrrithKhre Bescham, Philadelphia, PA, USA
In the recently-completed U.S. Carvedilol Heart Failure Trials Program, the
multiple-action, neurohormonal antagonist oarvadilol was found to reduce
mortality and cardiovascular-related hospitalization over a mean follow-up
period of 6.5 months oompared to placetm in patients with symptomatic con-
gestive heart failure (CHF) rsoeiving treatment with angiotensin-converting
enzyme inhibitors, digoxin, and diuretioa. We undertook an economic eval-
uation in conjunction with this program to examine the impact of cwvedilol
therapy on the mate of cardiovascular-related hospitalization. The utiliza-
tion of all cardiovascular-related inpatient services was documented for all
eubjects in this program, and costs (not charges) were aseigned using sec-
ondary data. The mean total cost of all cardiovascular-related admissions
was 62% lower among patients receiving cewedilol compared to those re-
ceiving placebo (mean + SD) $Iw + 6667vs $4327+ 20507 msP@ivelY)
(p= 0.01 by Wilcoxon rank-sum teat). Few-four percent ($1164) of these
aavings refleqted reduced numbers of cardiovascular-related admissions.
The remainder was attributable to reduced numbers of days in intensive-
care units per admission (1.47 + 2.85 vs 4.83 + 16.66). Cost aavings were
similar in patient aubgroupa defined by age, gender, etiology of CHF,ejection
fraction, and New York Hearl Ass~iation (NYHA) Class.
WI f3fectsofLong-TermCarVedilOIAdminiatration
in Patients with Idiopathic Dilated
Cardiomyopathy
M. Metra, S. Ncdari, D. Raccagni, M. Garbellini, E. Boldi, M. Grigolato,
F. Roeaelli, R. Zanini, L. Dei Cas. Cardiology, University of Brescia, /ta/y
Follow-up duration in previous controlled trials regarding cswedilol (carv)
in heart failure (HF) was s 1 year. We report the effects of long-term csrv
administration to pts with HF,first recruited ina4 months, placebo-controlled,
trial. All the 20 pts initially randomizedfo caw continued treatment with this
drug. Among them, 4 died (3 for cardiac and one for noncardiac causes)
and 2 undarwent hearl Tx. Among the 20 pts initially on placebo, 5 died for
cardiac causes, 3 underwent heatt Tx and 4 wera crossed over to carv for
worsening HF; the remaining 8 were used as control group. All pts were on
dig, fur and ACE-i and were asseased by MUGA, bicycle CPX testing and
MLHF questionnaire at baaeline, after 4 rots, 1year and 44 + 12 mts (range
40 to 53) of therapy. No difference was present at baseline between the two
groups. In the control group, LV EDVI increased from 126+62 to 136 +53
and 158 + 62 ml/m2 after 1 and 4 years; no other significant change was
found. Reeulte in the pts on caw are reported in the table (*p < 0.01).
EF (%) EDVI Peek V02 NYHA MLHF
BS 22* 6 147 *54 15.2 + 3.6 2.6 + 0.5 42& 16
4 mts 34* 11* 139 +51 t6.4 +4.0 1,9 * 0.3” 26+20
1year 37* 11* 113 +42 17,3 & 5.6 1.9+0.8” 30 i 22
4 ys. 37 i 13* 101 +44* 17,2 &5.3 2.0+ 1.0” 32• 24
These results show that sew may improve LV function and symptoms of
patienta with HF also during long-term therapy.
m1017147 Ambulatory Intermittent 6-month Low-doeaDobutamine Infusion in Severe Heart Failure:
DICE Multicenter Trial
DICE Coilaboretive Group. LWifuto“M. Negri”, Mi/ano, /ta/y
3S pts clinically atable for at least 48 hours with standard treatment, NYHA
claee Ill or IV, oardiac index (Cl) s 2.2 I’min–l ‘m’2 and EF s 30%, were
randomized in 13 Cardiology Departments, 19 to ambulatory intermittent
dobutamine (D) and 19 to optimal standard treatment (controls, C). D was
infused at 2,5 &g*kg-l ‘rein-l with a portable pump 48 h/week for 6 months.
Follow up visits were at 8 weeks and at 6 months. Primary study endpoint
was 2 hospitalizations for worsening of CHF (2H-CHF); changes in NYHA
class, of 6 minute walking test (6 mWT) and mortality were secondary end
points. Baseline characteristics were age 65 + 9 y (mean + SEM), NYHA
class 111/lV18/20, ejection fraction 22 + 1°/., Cl 1.89 + 0.07 1*rein-l ‘m-2
without difference between treatment groups. The primary endpoint of z 2H-
CHF was reached by 4 C pts, but by none in D group; NYHA class improved
significantly (table) only in D, while 6 mWT did not change vs baseline (298
+ 35 C, 299 + 29 D). 3 pts in C group died and 5 in D, p = ns (2 pts during
drug D infusion). Median time to death was 62 and 94 days in C and D
respectively,3 pts in D group underwent heart transplantation. Protocol was
discontinued in D group for severe ventricular arrhythmias (1 pt), consent
withdrawal (1 pt), and intolerance to infusion syatem (1 pt). In 3 D pts drug
dose waa increaaed to 5 Wg”kg-’”min-’ because of CHF.
No. group base 19C/19D 8w-base t8C/12D 6m-base 13C/6D
NYHA class c 3.58 + 0.11 –0.37 * 0,39 –1 .08+ 0,17
D 3.53 * 0.11 –1 * 0,249 2 + 0.679
Cl (1rein-l m-2) C 1.63 + 0.07 –0.09 * 0.09 n.a.
D 1.94 + 0.08 0.29 + O.leQ n.a.
mean + SEM; ‘p <0.05 vs C; ma.: notassessed.
6-month intermittent low-dose D was well tolerated, improved NYHAclaas
and Cl, and decreased hospitalizations in patients with severe CHF, without
the significant increase in mortality found with higher D doses in other studiea.
m1017148 Action of Amlodipine on Cytokine Levels: The
PRAISE Heart Failure Trial
E.R. Mohler Ill, L.C. Sorenson, J.K. Ghali, D. Schocken, P.W.Willis,
J.A. Bowers, A.B. Cropp, M.L. Pressler. The University of Penrwy/vania,
Phi/ade/phia, PA, USA
The molecular mechanism for progression of chronic heart failure (HF) may
involve cyfokine over-expression. in the PRAISE trial, we U8ed ELISA to aa-
say plasma levels of tumor necrosis factor alpha (TNF,n = 92) and interiaukin
6 (IL-6, n = 62) in patients with NYHA Class III-IV HF randomized to amlcdip-
ine (Amlo; 10 mg/day) or placebo (Plac). Baseline Amlo and Plac groups did
not differ in demographic and cytokine levels. Plasma levels (mean + SE)
of TNF were 5.69 + 0.32 pr#ml and IL-6 were 9.23 + 1.26 pg/ml at base-
Iina. These levels were elevated 6-times and 10-times, respectively, that of
controla (P < 0.001).
CytokineLevele (mean + SE in pg/ml)
Group Baseline 8 Weeks 26 Weeks
TNF Plac 5.2 & 0.4 5,5 * 0.4 5.5 & 0.4
TNF Amlo 6.3 & 0.6 7,2 & 1.2 6.6 * 1.0
IL-6 Plac 5.6 + 0.6 8.6 * 1.5 8.0 + 2.2
TNF Amlo 9.9 + 2.9 8.5 & 2.3 6.9 + 1.8
TNFdid not change significantly over the 26 week period (p= 0.69). How-
ever, IL-6 levels were significantly lower at 26 weeks in patienta treated with
amlodipine vs. placebo (p = 0.007, Signed Rank Test). Significant variables
predictive of suwival were IL-6 (p = 0.018) and NYHA clase (p = 0.025).
Thus, amlodipine seams to cause a reduction in IL-6 levels in patients with
congestive heart failure.
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\ 1018-31 I MitralValveMorpholOWandFUntiiOnbefOreand
afterLeftVentricularRemodelingSurgery
G.M. Scalia, P.M.McCarthy, R.C. Starling, A.J. Morahead, R.L. Vargo,
TM. Buda, J.D. Thomas. C/eve/and Clinic Foundation, C/eve/and, 0/-/, USA
The left ventricular remodeling’procedure (LVR) for congestive hearI failure
involves excision of the entire posterolateral LV wall with approximation of
the papillary muscles. The resultant lengthening of the chordal apparatus
has been countered by a unique valvuloplasty procedure: tacking of the mid-
portion of the anterior and posterior leaflets, with or without annuloplasty ring
support.
